Metabolism and response to anti-CGRP treatments in migraine

It is plausible, owing to the differing response of patients with migraine to CGRP-receptor monoclonal antibodies, that there are subgroups or categories of migraine which are experienced differently from one another. Elizabeth Leroux, MD, FCRP, University of Calgary, Canada, outlines the possibility of a metabolic migraine in which there are dominant metabolic factors. It is known that patients resistant to CGRP-receptor antibodies often have a large metabolic load and mental stressors, which may contribute to this resistance to antibody treatment. More research is required to determine if targeting metabolic factors in these patients may allow for a CGRP-receptor antibody response or if not CGRP led, may alleviate symptoms independently. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.